Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network - sprookjes - yvandenbroek - TriplyDB

Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network

Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network

http://www.wikidata.org/entity/Q28220911

about

Mechanism of action of lenalidomide in hematological malignancies Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma Multiple myeloma Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial.Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma.Management of the adverse effects of lenalidomide in multiple myeloma.Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.Practical approaches to the use of lenalidomide in multiple myeloma: a canadian consensus.Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy.Compromising the unfolded protein response induces autophagy-mediated cell death in multiple myeloma cells.Lenalidomide in multiple myeloma: current experimental and clinical data.Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.Immunomodulatory drugs in multiple myeloma.Emergence of oligoclonal bands in patients with multiple myeloma in complete remission after induction chemotherapy: association with the use of novel agents Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report.Lenalidomide in the treatment of multiple myeloma: a review.Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3 IMWG consensus on maintenance therapy in multiple myeloma.Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma.Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma Bone marrow microenvironment and the identification of new targets for myeloma therapy.Synthesis of hapten and preparation of specific polyclonal antibody with high affinity for lenalidomide, the potent drug for treatment of multiple myeloma Thalidomide and its analogues in the treatment of Multiple Myeloma Early response to bortezomib combined chemotherapy can help predict survival in patients with multiple myeloma who are ineligible for stem cell transplantation.Trace determination of lenalidomide in plasma by non-extractive HPLC procedures with fluorescence detection after pre-column derivatization with fluorescamine.Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.An update on drug combinations for treatment of myeloma.Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma.Treatment of plasma cell dyscrasias with lenalidomide.Lenalidomide and its role in the management of multiple myeloma.Modern treatment options for elderly patients with multiple myeloma.Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement.Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma.Role of thalidomide in previously untreated patients with multiple myeloma.Treatment of newly diagnosed myeloma.

P2860

Q21198872-67CD0460-2A7F-4B81-967C-7A30054D9B1D Q21285161-7F2D9D45-883C-41F6-896B-C5726633E311 Q24655964-AC96F703-BB7E-4C6C-A73C-4248A11299C4 Q33386405-C9255EE3-DAA7-4A06-A86F-C33811257383 Q33387733-C8ACBC8C-ED8E-4953-A4D4-F3DA8CF134A8 Q33389075-6B1A113E-7A61-469B-9B31-815BE3AC241B Q33394632-C2C63478-0EF4-4BDB-B916-D31D1B37C990 Q33400424-AA4D1A10-0285-4173-8C8E-0B52DEF48070 Q33404007-73F3ABDC-70D6-4126-B08B-C8F9530004A6 Q33639796-264FBF69-F0BA-4A06-ABC0-58B877E2B3DC Q33710994-C411F8A3-71CC-4CF8-B035-A9F4CFB84F46 Q33973877-8C5FC5DB-A3B7-4D45-97CD-224B230D4F0D Q34058325-73EFB725-944B-4639-8BE2-0911906D68AC Q34074803-33E7F9CF-EC1F-435B-9D86-99233D629AB7 Q34253548-1DF462A3-C79B-497F-A38B-75F1D2FBD827 Q34325722-B6F8FBAC-5D31-4085-9B49-05EFA7C415B6 Q34451635-AAB7860E-790F-4A4F-B31E-21B55964BE71 Q34666858-2D2DA800-66A9-49D8-8CE1-66E25A47F960 Q34775515-CD114281-09B9-499B-AC8C-17BA0F774700 Q35266125-1E4BE200-D5D1-41DD-BA28-A12B85683F65 Q35876966-FB8A549E-4F92-4658-BE11-20654D8EE28F Q36051084-05761BB9-0DDE-46C9-8D32-20C754A4C5DD Q36148528-C8DB4FD4-6437-4213-89E5-C3978A90A09C Q36162703-E1955356-BE33-4D34-9A23-249784178F73 Q36394469-8F699E50-067A-4F99-A46E-9D16349916F6 Q36444523-578D5B0E-DADF-4581-840F-F5D6A2074878 Q36536365-697BD35B-90F3-4D30-A9B8-43B409976F37 Q36744385-D97B10A5-EBD1-4DCC-9179-AE43D2FE11C0 Q36805878-2DA7D9FC-83FB-4EAE-BDBF-379F1AF3F2D3 Q36963203-74E87C8B-C649-4668-B9DE-60911B5D10F6 Q37038414-84208DBB-AD12-4E91-A4B0-3794ECEFDABB Q37038973-A25077F9-43CD-4083-B170-354C0527D5CE Q37162610-25473781-E739-4380-9043-EC7014540B25 Q37176044-1E571F4B-38B6-4CA4-8D0E-B215038ED95C Q37183439-61D60820-A43E-4C02-AF45-38868F3E2305 Q37189281-5825173E-5821-4A37-86D5-9E4B127F4DB0 Q37212712-C520F9BE-8C07-45E5-815B-30B2F1269923 Q37228026-711F4EF7-335B-4833-9DCA-34E34C6781CE Q37300004-831FB704-5C4C-45A5-8552-1E1D9FD2B25C Q37324251-9E81311B-06EA-4433-A4FD-50FE486359DB

P2860

Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network

http://www.wikidata.org/entity/Q28220911

description

2007 nî lūn-bûn

@nan

2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Melphalan, prednisone, and len ...... alian Multiple Myeloma Network

@ast

Melphalan, prednisone, and len ...... alian Multiple Myeloma Network

@en

Melphalan, prednisone, and len ...... alian Multiple Myeloma Network

@nl

type

label

Melphalan, prednisone, and len ...... alian Multiple Myeloma Network

@ast

Melphalan, prednisone, and len ...... alian Multiple Myeloma Network

@en

Melphalan, prednisone, and len ...... alian Multiple Myeloma Network

@nl

prefLabel

Melphalan, prednisone, and len ...... alian Multiple Myeloma Network

@ast

Melphalan, prednisone, and len ...... alian Multiple Myeloma Network

@en

Melphalan, prednisone, and len ...... alian Multiple Myeloma Network

@nl

P1433

Q28220911-65673244-E299-46DE-B373-551906095240

P1476

Q28220911-BC0FD6F6-5B36-4CA3-B177-20661410D0E6

P2093

Q28220911-115F8835-F4F3-4725-A955-B68848BCDC04

Q28220911-2177F030-D1B3-464C-9459-360F3A4610A2

Q28220911-379D7DE7-DD4B-4566-AD70-65239DFD06AF

Q28220911-42194ADF-A3C6-40AE-8211-CA18551531A1

Q28220911-61446765-ECCD-40F6-8759-C78D0642660F

Q28220911-827B0299-8BC4-43A1-951F-83C378E695DB

Q28220911-A0295EE0-7374-428D-809C-5A21CC133F9A

Q28220911-DA020F43-68BA-45F8-84FC-20FD4FCFCAD4

Q28220911-E0472DEC-509E-4CFC-BFB6-3A9301711012

Q28220911-E0856D41-3365-4DC6-B930-7A3EA570A56E

P304

Q28220911-7901B236-7BE9-4903-B5CE-710309EB3560

P31

Q28220911-CB37E8C2-D267-4311-A12D-CCCFD118883C

P356

Q28220911-DAA64A71-71F6-4F8A-A365-1F9B663B3A8C

P407

Q28220911-77871899-E6CA-4F2D-AF34-1EE8CB328FDD

P433

Q28220911-8327560A-584C-49FC-ABED-9E68AEB3FB1A

P478

Q28220911-1E0808CD-E380-45D3-BA1B-82AA40970998

P50

Q28220911-507DC0D8-F23C-432B-A43A-E68B011905BB

Q28220911-56BC8343-42DA-405C-97C7-2239AFDA53F6

Q28220911-63E3399C-C8D6-4073-AFF3-665D07C0C3CE

Q28220911-6A5C6E49-AF34-484B-BD87-DEBD9C24D182

Q28220911-8A81FA37-0B68-4F0F-9DED-C25988E5BD7F

Q28220911-CC47B1FC-5033-42AA-A255-5773038B6E35

Q28220911-FA6ED8C3-340F-4449-B189-D5112A252CF2

P577

Q28220911-CD4D6F52-246F-4332-9E9C-3F50C4DADE23

P5875

Q28220911-858A7B82-5169-4CF3-93CC-11D6382A2A9B

P698

Q28220911-3D92DE1F-2CB4-4BE8-8CFB-896974BA834A

P921

Q28220911-A704A53A-110E-4D35-AE53-BD4F140A1205

P356

JCO.2007.12.3463

P1433

Journal of Clinical Oncology

P1476

Melphalan, prednisone, and len ...... alian Multiple Myeloma Network

@en

P2093

Antonietta Falcone

http://www.w3.org/2001/XMLSchema#string

Claudia Crippa

http://www.w3.org/2001/XMLSchema#string

Francesca Gay

http://www.w3.org/2001/XMLSchema#string

Jerome B Zeldis

http://www.w3.org/2001/XMLSchema#string

Maria Teresa Ambrosini

http://www.w3.org/2001/XMLSchema#string

Maria Teresa Petrucci

http://www.w3.org/2001/XMLSchema#string

Mario Boccadoro

http://www.w3.org/2001/XMLSchema#string

Paola Omedè

http://www.w3.org/2001/XMLSchema#string

Patrizia Falco

http://www.w3.org/2001/XMLSchema#string

Robert Knight

http://www.w3.org/2001/XMLSchema#string

P304

4459-65

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2007.12.3463

http://www.w3.org/2001/XMLSchema#string

P407

P433

28

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P50

Paolo Corradini

Francesco Di Raimondo

Pellegrino Musto

Giovannino Ciccone

Nicola Giuliani

Antonio Palumbo

P577

2007-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6054233

http://www.w3.org/2001/XMLSchema#string

P698

17785703

http://www.w3.org/2001/XMLSchema#string

P921